Vitro Biopharma is an innovative biotechnology company focused on developing Wharton's jelly-derived cell therapies for autoimmune diseases and inflammatory disorders. Our goal is to become a leader in developing differentiated product candidates in a rapid and efficient manner for the immunology and inflammatory market.
We manufacture under strict environmental and laboratory controls in accordance with cGMP. We are cGMP compliant with a QMS that is globally recognized as ISO 9001:2015 and ISO 13485:2016 certified. With 30 years of research and by leveraging the biological advantages of UC-derived MSCs, we believe we may have a significant cost and competitive advantage over our competitors, within our scalable and standardized manufacturing process.